Literature DB >> 5557914

Immune function in multiple myeloma: impaired responsiveness to keyhole limpet hemocyanin.

J Harris, R Alexanian, E Hersh, P Migliore.   

Abstract

Twenty-three patients with multiple myeloma, four patients with treated localized plasmacytoma and 14 normal subjects were immunized with keyhole limpet hemocyanin (KLH). When compared to the normal subjects, the myeloma patients showed a prolonged induction time for IgM antibody formation, a more rapid switch from IgM to IgG production and a decline in the titre of total antibody produced. In vitro lymphocyte responses to KLH following immunization were reduced in the myeloma group and tended to decline with time in a manner similar to the serum antibody concentration. Most of the myeloma patients tested developed delayed hypersensitivity skin reactions to KLH, but these reactions were smaller than those of the control subjects. The patients with myeloma had also reduced in vitro lymphocyte responses to streptolysin-O and vaccinia. Immune function of the plasmacytoma patients was similar to that of the control subjects.Both humoral and cellular immunity in response to a newly encountered antigen, KLH, is impaired in patients with multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5557914      PMCID: PMC1930886     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  14 in total

1.  INFECTION, ANTIBODY RESPONSE AND GAMMA GLOBULIN COMPONENTS IN MULTIPLE MYELOMA AND MACROGLOBULINEMIA.

Authors:  J L FAHEY; R SCOGGINS; J P UTZ; C F SZWED
Journal:  Am J Med       Date:  1963-11       Impact factor: 4.965

2.  Recurrent pneumonia in multiple myeloma and some observations on immunologic response.

Authors:  H H ZINNEMAN; W H HALL
Journal:  Ann Intern Med       Date:  1954-12       Impact factor: 25.391

3.  Micromethods for the study of proteins and antibodies. I. Procedure and general applications of hemagglutination and hemagglutination-inhibition reactions with tannic acid and protein-treated red blood cells.

Authors:  A B STAVITSKY
Journal:  J Immunol       Date:  1954-05       Impact factor: 5.422

4.  The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation.

Authors:  J E Curtis; E M Hersh; J E Harris; C McBride; E J Freireich
Journal:  Clin Exp Immunol       Date:  1970-04       Impact factor: 4.330

5.  Immunosuppressive therapy. The relation between clinical response and immunologic competence.

Authors:  M A Swanson; R S Schwartz
Journal:  N Engl J Med       Date:  1967-07-27       Impact factor: 91.245

6.  Abnormal nucleic acid metabolism of lymphocytes in plasma cell myeloma and macroglobulinemia.

Authors:  S E Salmon; H H Fudenberg
Journal:  Blood       Date:  1969-02       Impact factor: 22.113

7.  IgE in lymphoid cells from pollen-stimulated cultures.

Authors:  J Brostoff; M F Greaves; I M Roitt
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

8.  Immunosuppressive effects of cytosine arabinoside and methotrexate in man.

Authors:  M S Mitchell; M E Wade; R C DeConti; J R Bertino; P Calabresi
Journal:  Ann Intern Med       Date:  1969-03       Impact factor: 25.391

9.  Macrophage-lymphocyte interaction in the antigen-induced blastogenic response of human peripheral blood leukocytes.

Authors:  E M Hersh; J E Harris
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

10.  Human immune response to a xenogeneic nucleated cell.

Authors:  J E Harris; E M Hersh; S Huggins
Journal:  Transplantation       Date:  1970-05       Impact factor: 4.939

View more
  5 in total

1.  Lymph node plasmacytoma in a child: clinical and immunological findings with special reference to S-Ig and complement receptor subtypes.

Authors:  K Kruse; H Stein; W H Hitzig; P Joller; U Lasson
Journal:  Eur J Pediatr       Date:  1978-12-01       Impact factor: 3.183

2.  Severe deficiency of B lymphocytes in peripheral blood from multiple myeloma patients.

Authors:  L M Pilarski; M J Mant; B A Ruether; A Belch
Journal:  J Clin Invest       Date:  1984-10       Impact factor: 14.808

3.  Humoral immune deficiency in multiple myeloma patients due to compromised B-cell function.

Authors:  L M Pilarski; E J Andrews; M J Mant; B A Ruether
Journal:  J Clin Immunol       Date:  1986-11       Impact factor: 8.317

4.  Should patients with renal failure associated with myeloma be dialysed?

Authors:  R A Coward; N P Mallick; I W Delamore
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-26

5.  Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients.

Authors:  Sebastian Kobold; Tim Luetkens; Britta Marlen Bartels; Yanran Cao; York Hildebrandt; Orhan Sezer; Henrike Reinhard; Julia Templin; Katrin Bartels; Nesrine Lajmi; Friedrich Haag; Carsten Bokemeyer; Nicolaus Kröger; Djordje Atanackovic
Journal:  Clin Dev Immunol       Date:  2012-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.